Europe Gene Editing Technology Business and Investment Opportunities Databook - Q2 2023 Update

According to the publisher, Europe gene editing technology market size is expected to record a CAGR of 22.4% during 2023-2027 to reach US$2.516 billion by 2027, increasing from US$0.914 billion in 2023. Over the last five years, the sector has recorded a CAGR of 28.7% to reach US$0.710 billion in 2022.

This offering is a bundled offering, combining 5 countries and a key report covering European region.This report provides an in-depth data-centric analysis of the emerging opportunities in the gene editing industry. It covers a detailed view of market size and forecast across various segments such as gene editing technologies (CRISPR, meganucleases, TALEN, and ZFN), by products, delivery method, disease/disorders, and application.

This title is a bundled offering, combining the following 6 reports, covering 210+ tables and 264+ figures:

• Country Report 1- Europe Gene Editing Technology Business and Investment Opportunities Databook - Q2 2023 Update
• Country Report 2- France Gene Editing Technology Business and Investment Opportunities Databook - Q2 2023 Update
• Country Report 3 - United Kingdom Gene Editing Technology Business and Investment Opportunities Databook - Q2 2023 Update
• Country Report 4 - Switzerland Gene Editing Technology Business and Investment Opportunities Databook - Q2 2023 Update
• Country Report 5 - Italy Gene Editing Technology Business and Investment Opportunities Databook - Q2 2023 Update
• Country Report 6 - Germany Gene Editing Technology Business and Investment Opportunities Databook - Q2 2023 Update

Scope

This report provides an in-depth, data-centric analysis of the Europe's gene editing market 2018-2027. Below is a summary of key market segments:

By Technology

• CRISPR CAS 9
• TALENs
• ZFN
• Others (Meganucleases)

By CRISPR PRODUCTS

• Kits & Enzymes
• Cell lines & Antibodies
• Others (Plasmid, Controls)

By TALENs PRODUCTS

• Kits & Enzymes
• Cell lines & Antibodies
• Others (Plasmid, Controls)

By ZFNs PRODUCTS

• Kits & Enzymes
• Cell lines & Antibodies
• Others (Plasmid, Controls)

By Meganucleases PRODUCTS

• Kits & Enzymes
• Cell lines & Antibodies
• Others (Plasmid, Controls)

By Delivery Method

• Ex-vivo
• In-vivo

By Disease/Disorders

• Cancer
• Blood Disorders (beta-thalassemia and sickle cell disease)
• Blindness
• Respiratory Disease (COVID-19 & Cystic fibrosis)
• Others (AIDS, Huntington’s disease, Muscular dystrophy)

By Application

• Drug Development
• Diagnostics
• Plant Gene Editing
• Others (Animal Gene Editing)

By End-User

• Pharmaceutical and Biopharmaceutical Companies
• Biotechnology Companies
• Contract Research Organisations
• Academic Institutes and Research Centres